Disease · EFO_0700108

non-infectious posterior uveitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. non-infectious posterior uveitis. Diseases, record EFO_0700108. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0700108

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: non-infectious posterior uveitis; Open Targets
Open Targets ID: EFO_0700108; Open Targets
Other names: non-infectious choroiditis; Open Targets
Orphanet: ORPHA:90061; Orphanet
Highest stage of its drugs: Phase 3, for 2 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
GEVOKIZUMAB	CHEMBL1743026	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TESIDOLUMAB	CHEMBL4298012	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
C5	Complement C5	1	Complement C5 binding agent	Phase 2	https://conductscience.org/library/genes/727	Drugs and targets
IL1B	Interleukin-1 beta	1	Interleukin-1 beta negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/3553	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 1	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Phase 3	https://conductscience.org/library/genes/7124	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03828019	Adalimumab vs. Conventional Immunosuppression for Uveitis Trial	Phase 3	227	2025-05-16	Uveitis	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT01526889	Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,	Phase 2	25	2018-10-31	Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis	TESIDOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01684345	Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis	Phase 3	200		Uveitis	GEVOKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02258854	An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data	Phase 3	69		Uveitis	GEVOKIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04120311	Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole	Phase 1	2		Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Adalimumab (ADA) vs Conventional Immunosuppression (CON): deaths from any cause	0 of 113	0 of 110	223	NCT03828019	Trial comparisons
Adalimumab (ADA) vs Conventional Immunosuppression (CON): serious adverse events	16 of 113	13 of 110	223	NCT03828019	Trial comparisons
LFG316 vs Conventional Therapy: Number of Participants With Remission in Study Eye - Treatment Period	2 of 18	0 of 7	25	NCT01526889	Trial comparisons
LFG316 vs Conventional Therapy: deaths from any cause	0 of 18	0 of 7	25	NCT01526889	Trial comparisons
LFG316 vs Conventional Therapy: serious adverse events	1 of 18	0 of 7	25	NCT01526889	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38925285	DERIVED	1	PubMed
37172782	DERIVED	1	PubMed
36912792	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0700108

GET https://conductscience.org/api/diseases/v1/EFO_0700108/drugs

API reference For AI assistants